It was reported that the patient was discharged from study center to rehabilitation facility on 23jun2022.On 28jun2022 the patient reported dyspnea and required 2 liters of oxygen, which resulted in an oxygen saturation of 90-96%.Pleural effusion was seen in the ultrasound with a distended interior vena cava.The patient was progressively somnolent and was transferred to the emergency department of the study center with a mean arterial pressure if 100 mmhg.A thoracic x-ray showed moderate signs of congestion.The infection parameters were elevated however there was no sign of infection focus detectable in x-ray, urine stick analysis and thoracic and abdominal computed tomography imaging.The patient received ebantil perfusor due to hypertension and levosimendan perfusor for myocardial support upon hospitalization.The clinical state of the patient rapidly improved.
|
Manufacturer's investigation conclusion: a direct correlation between heartmate 3 left ventricular assist system (lvas), serial number (b)(6), and the reported events could not be conclusively determined through this evaluation.The patient remains ongoing on heartmate 3 lvas, serial number (b)(6), with no further issues reported at this time.The relevant sections of the device history records for (b)(6) were reviewed and showed no deviations from manufacturing or quality assurance specification.The heartmate 3 left ventricular assist system (lvas) instructions for use (ifu), rev.G, is currently available.Section 1, ¿introduction¿, lists the adverse events that may be associated with the use of the heartmate 3 lvas, including hypertension.No further information was provided.The manufacturer is closing the file on this event.
|